公开(公告)号：WO2014176373A2

公开(公告)日：2014-10-30

申请号：PCT/US2014/035201

申请日：2014-04-23

申请人： ARMO BIOSCIENCES, INC.

发明人： MCCAULEY, Scott ,  VAN VLASSELAER, Peter

IPC分类号： A61K38/20

CPC分类号： C07K14/5428 ,  A61K9/0019 ,  A61K38/2066 ,  A61K39/3955 ,  A61K47/48215 ,  A61K47/60 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/92 ,  G01N33/6869

摘要： Interleukin-10 muteins and other interleukin-10 - related molecules are described, as well as methods of identifying interleukin-10 muteins and other interleukin-10 - related molecules. Also described herein are modifications of the foregoing, which modifications may enhance a property (e.g., half-life) of the muteins or other molecules compared to human interleukin-10. Particular interleukin-10 muteins and related molecules have comparable immunogenicity to human interleukin-10 and/or bioactivity at least comparable to human interleukin-10. Pharmaceutical compositions and methods of use are also described herein.

摘要翻译： 介绍了白介素-10突变蛋白和其他白细胞介素-10相关分子，以及鉴定白细胞介素-10突变蛋白和其他白细胞介素-10相关分子的方法。 本文还描述了前述的修饰，与人白细胞介素-10相比，这些修饰可增强突变蛋白或其它分子的性质（例如半衰期）。 特异性白细胞介素-10突变蛋白和相关分子与人白介素-10和/或至少与人白细胞介素-10相当的生物活性具有相当的免疫原性。 本文还描述了药物组合物和使用方法。

公开(公告)号：WO2017123557A1

公开(公告)日：2017-07-20

申请号：PCT/US2017/012882

申请日：2017-01-10

申请人： ARMO BIOSCIENCES, INC.

发明人： MUMM, John Brian ,  CHAN, Ivan Ho ,  MCCAULEY, Scott ,  OGG, Scott ,  OFT, Martin

IPC分类号： A61K39/00 ,  A61K39/02 ,  A61K39/12 ,  A61K39/39

CPC分类号： A61K39/39 ,  A61K38/2066 ,  A61K39/0011 ,  A61K2039/55527 ,  A61K2039/572

摘要： The present disclosure provides methods and compositions relating to isolated CD8+ T cells expressing a disease antigen-specific T cell receptor, as well as nucleic acids encoding the Vα and Vβ polypeptide pairs of T cell receptors (TCRs) of such disease antigen-specific T cells. Such disease antigen-specific CD8+ T cells are obtainable from the periphery (e.g., blood) of a subject having a disease amenable to treatment with an IL-10 agent. The present disclosure also contemplates therapeutic methods and compositions relating to administration of isolated disease antigen-specific CD8+ T cells to a subject, as well as therapeutic methods and compositions relating to CD8+ T cells genetically modified to express a disease antigen-specific TCR and/or chimeric antigen receptor.

摘要翻译： 本公开内容提供了涉及表达疾病抗原特异性T细胞受体的分离的CD8 + T细胞以及编码T细胞受体（TCR）的Vα和Vβ多肽对的核酸的方法和组合物， 的这种疾病抗原特异性T细胞。 此类疾病抗原特异性CD8 + T细胞可从具有适于用IL-10剂治疗的疾病的受试者的外周（例如血液）获得。 本公开还涵盖与给予受试者的分离的疾病抗原特异性CD8 + T细胞有关的治疗方法和组合物，以及涉及经遗传修饰以表达疾病抗原特异性TCR和/或CD8 + T细胞的治疗方法和组合物 嵌合抗原受体。

公开(公告)号：WO2016060996A3

公开(公告)日：2016-04-21

申请号：PCT/US2015/055156

申请日：2015-10-12

申请人： ARMO BIOSCIENCES, INC.

发明人： MCCAULEY, Scott

IPC分类号： A61K39/395

摘要： Interleukin-15 muteins and other interleukin-15 - related molecules are described, as well as methods of identifying interleukin-15 muteins and other interleukin-15 - related molecules. Also described herein are modifications of the foregoing, which modifications may enhance a property (e.g., half-life) of the muteins or other molecules compared to human interleukin-15. Pharmaceutical compositions and methods of use are also described herein.

公开(公告)号：WO2019094265A1

公开(公告)日：2019-05-16

申请号：PCT/US2018/058824

申请日：2018-11-02

申请人： ARMO BIOSCIENCES, INC.

发明人： MCCAULEY, Scott

IPC分类号： A61K39/395 ,  C07K16/18 ,  C07K16/22 ,  C07K16/28

CPC分类号： C07K16/2818 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/76 ,  C07K2317/92

摘要： The present disclosure provides polypeptide binding molecules that bind to Programmed Cell Death-1 (PD-1) and inhibit PD-1 interaction with both Programmed Cell Death Ligand-1 (PD-L1) and/or Programmed Cell Death Ligand-2 (PD-L2). The present disclosure further provides pharmaceutical formulations comprising the molecules of the present invention. The present disclosure further provides methods of use of such polypeptide binding molecules in the treatment of various disorders and diseases. The present disclosure further provides recombinant nucleic acid sequences encoding such polypeptide binding molecules and cells transformed therewith. The present disclosure also provides methods of use of the molecules of the present invention in the diagnosis, prevention and treatment of various disorders or conditions in subjects including but not limited to the treatment of neoplastic disorders including but not limited to cancer.